tirzepatide dosage compared to semaglutide Switching from Tirzepatide: What You Need to Know Efficacy of tirzepatide 5, 10

2002;50(11):178995 Accessed May 27, 2018

Purpose-built for physicians GLP1s may lower 10-year risk for major adverse outcomes in chronic liver disease, diabetes Key takeaways: The 10-year risk for major adverse liver outcomes was 13.3% among initiators vs

The primary outcome was percentage weight loss after 68-week treatment on an intention-to-treat analysis

(But) the older you are, the less evidence there is from any trial about you, because most of these trials havent really enrolled people over 70 or 80, so we need to continue to learn and see how this works

This editorial discusses the role of lifestyle interventions in obesity treatment, emphasizing their importance even with the advent of pharmacotherapy Golovaty I, Hagan S

Create a nutrition plan that includes fiber, staying hydrated, and timing your meals well